Go to content

Call For Abstracts

Call For Abstracts

Guidelines for Abstract Submission
Structure of the Abstract
Author Agreement
Important Dates

The abstract submission is closed.

Scientific Committee would like to thank everyone who has submitted an abstract.

Deadline for abstract submission was 20 December 2012, 8pm local UAE time.

Guidelines for Abstract Submission 
A special criterion for accepting abstracts will be their topic as well as structure, content and degree of novelty.

Structure of the Abstract 
The structure of the abstract should be as follows:
a. Background and Objectives
b. Methods
c. Results
d. Conclusions

Please note that a maximum of 300 words is permitted. The titles and the names of the authors are excluded from this number and have to be entered separately. Tables should not be included in the abstract body.
Methods section should include type of statistical analysis done if applicable to the study.


  • Tumor progression: basic and therapeutic aspects
  • Cancer biomarkers
  • Aberrant signaling pathways in malignancy
  • Novel targeted therapy in cancer
  • Chemotherapy resistance
  • Pharmacogenomics, personalized diagnostics and medicine
  • Genome project on drug development and cancer therapy
  • Epigenetics and its impact on cancer therapy

  • Author Agreement 
    By submitting the abstract, the author confirms and agrees to the following:
    a. All authors approve submitting this work for presentation.
    b. The authors have done the work reported in the abstract and take full responsibility for the contents.
    c. The authors transfer all copyright ownership of the abstract to the PMTC2013.
    d. The authors agree to confine their presentation to information in the abstract.
    e. At least one author will be available to present the abstract if accepted for presentation.
    f. The author will immediately notify the PMTC2013 Scientific Committee if they are unable to make a presentation or if the presenting author has to be changed.
    g. The authors guarantee that clinical studies and any animal tests have proceeded with the official permission from the proper authorities.
    h. All presenters will be responsible for their own registration fees, hotel and travel expenses. We regret that we cannot waive registration fees or cover expenses for any oral or poster presenters.

    Important Dates

    1 May 2012

    Abstract submission opens for poster and oral presentations

    20 Dec 2012

    Deadline for abstract submission - EXTENDED

    05 Jan 2012

    Abstract acceptance notification to first authors

    1 Dec 2012

    All presenting authors must be registered

    Back to content | Back to main menu